AU2006210994A1 - Assays for agents with selective cytotoxicty to HDAC resistant cell lines - Google Patents

Assays for agents with selective cytotoxicty to HDAC resistant cell lines Download PDF

Info

Publication number
AU2006210994A1
AU2006210994A1 AU2006210994A AU2006210994A AU2006210994A1 AU 2006210994 A1 AU2006210994 A1 AU 2006210994A1 AU 2006210994 A AU2006210994 A AU 2006210994A AU 2006210994 A AU2006210994 A AU 2006210994A AU 2006210994 A1 AU2006210994 A1 AU 2006210994A1
Authority
AU
Australia
Prior art keywords
hdaci
resistant
test agent
inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006210994A
Other languages
English (en)
Inventor
Nicholas Edwards
Torsten Nielsen
Maxwell Sehested
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget UK Ltd
Original Assignee
Topotarget UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget UK Ltd filed Critical Topotarget UK Ltd
Publication of AU2006210994A1 publication Critical patent/AU2006210994A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006210994A 2005-02-07 2006-02-06 Assays for agents with selective cytotoxicty to HDAC resistant cell lines Abandoned AU2006210994A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65014105P 2005-02-07 2005-02-07
US60/650,141 2005-02-07
PCT/GB2006/000425 WO2006082448A1 (fr) 2005-02-07 2006-02-06 Dosages d'agents ayant une cytotoxicite selective envers les lignees cellulaires hdac-resistantes

Publications (1)

Publication Number Publication Date
AU2006210994A1 true AU2006210994A1 (en) 2006-08-10

Family

ID=35978552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006210994A Abandoned AU2006210994A1 (en) 2005-02-07 2006-02-06 Assays for agents with selective cytotoxicty to HDAC resistant cell lines

Country Status (5)

Country Link
EP (1) EP1856522A1 (fr)
JP (1) JP2008529487A (fr)
AU (1) AU2006210994A1 (fr)
CA (1) CA2596405A1 (fr)
WO (1) WO2006082448A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627500T3 (es) 2012-07-13 2017-07-28 Turun Yliopisto Terapia de combinación
JP6294614B2 (ja) * 2013-05-08 2018-03-14 有限会社マイテック 癌関連物質の定量方法
CN107954893A (zh) * 2017-11-28 2018-04-24 兰州纬寰生物科技有限公司 邻氨基苯甲酰胺衍生物及制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US20010053773A1 (en) * 1998-12-22 2001-12-20 The Procter & Gamble Company Method for inhibiting the growth of cancers
US20080233562A1 (en) * 2003-02-19 2008-09-25 Astellas Pharma Inc. Method of Estimating Antitumor Effect of Histone Deacetylase Inhibitor

Also Published As

Publication number Publication date
CA2596405A1 (fr) 2006-08-10
WO2006082448A1 (fr) 2006-08-10
EP1856522A1 (fr) 2007-11-21
JP2008529487A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
US6511990B1 (en) Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US20220160721A1 (en) Methods of treating cancer
EP1427403B1 (fr) Acide valproique pour le traitement des cancers du sein, du colon, de la tête et du cou, du carcinome du poumon à petites cellules et du cancer de cellules sanguines en combinaison avec l'irradiation
US7550490B2 (en) Benzamide derivatives as histone deacetylase inhibitors with potent differentiation and anti-proliferation activity
CA2552279C (fr) Acides gras a chaine courte lies a un motif de chelation zn<sp>2+</sp> utilises en tant que nouvelle classe d'inhibiteurs d'histone desacetylase
US8236985B2 (en) Compounds and uses thereof
CN103764604B (zh) 茋类似物和治疗癌症的方法
JP4644829B2 (ja) ヒストン脱アセチル化酵素阻害剤としての新規な化合物
US10758513B2 (en) Modulators of mitochondrial protein import
JP2011516473A (ja) 医薬組成物
AU2006210994A1 (en) Assays for agents with selective cytotoxicty to HDAC resistant cell lines
WO2008068170A1 (fr) Inhibiteurs de l'hdac
JP2024023269A (ja) 抗腫瘍剤及び配合剤
US7351861B2 (en) Method and probe for identifying bacterial virulence modifying agents, agents thus identified, and their use
Kortenhorst et al. Acetylation and histone deacetylase inhibitors in cancer
US20040198727A1 (en) Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments
CN117756742A (zh) 苯并噻唑类化合物或其盐、其制备方法及应用
JP4150792B2 (ja) 血液脳関門におけるキノリン酸の輸送を評価する方法
AU2002231190A1 (en) Methods for inducing apoptosis and inhibiting proliferation in cancer cells
WO2002051406A9 (fr) Methodes permettant d'induire l'apoptose et d'inhiber la proliferation de cellules cancereuses
WO2020257753A1 (fr) Inhibiteurs de la phosphatidylsérine décarboxylase
AU2007207869B2 (en) Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period